🇪🇺·Aug 26Research
A phase I clinical study of the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-2106, an anti-CD40 antibody, following single intravenous or subcutaneous administration in healthy participants.
Publisher
E
Europe PMC
EU
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Europe PMC
- Region
- EU
- Scope
- Research
- Published
- August 26, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on europepmc.org
Leave the platform to read the original full article on the publisher site.
Source: Europe PMC
Scope: Research
Related coverage
More related coverage
Crossref/14h ago
Evaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patients
Crossref/14h ago
Polycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Prediction
Crossref/14h ago
Low-Dose Silodosin for Premature Ejaculation: A Clinical Evaluation
Crossref/14h ago